Marble Harbor Investment Counsel Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Marble Harbor Investment Counsel reduced its stake in Abbott Laboratories by 0.19% during the most recent quarter end. The investment management company now holds a total of 255,325 shares of Abbott Laboratories which is valued at $11,502,391 after selling 480 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Abbott Laboratories makes up approximately 2.76% of Marble Harbor Investment Counsel’s portfolio.

Other Hedge Funds, Including , Kidder Stephen W boosted its stake in ABT in the latest quarter, The investment management firm added 8,350 additional shares and now holds a total of 120,280 shares of Abbott Laboratories which is valued at $5,418,614. Abbott Laboratories makes up approx 2.09% of Kidder Stephen W’s portfolio.Royal London Asset Management Ltd reduced its stake in ABT by selling 42,994 shares or 7.95% in the most recent quarter. The Hedge Fund company now holds 497,834 shares of ABT which is valued at $22,377,638. Abbott Laboratories makes up approx 0.35% of Royal London Asset Management Ltd’s portfolio.Diligent Investors reduced its stake in ABT by selling 66 shares or 0.69% in the most recent quarter. The Hedge Fund company now holds 9,449 shares of ABT which is valued at $422,843. Abbott Laboratories makes up approx 0.38% of Diligent Investors’s portfolio.Blb&b Advisors boosted its stake in ABT in the latest quarter, The investment management firm added 230 additional shares and now holds a total of 66,050 shares of Abbott Laboratories which is valued at $2,817,033. Abbott Laboratories makes up approx 0.52% of Blb&b Advisors’s portfolio.

Abbott Laboratories opened for trading at $45.2 and hit $45.23 on the upside on Monday, eventually ending the session at $45.15, with a gain of 0.24% or 0.11 points. The heightened volatility saw the trading volume jump to 65,25,830 shares. Company has a market cap of $66,370 M.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *